课题基金 / 基金详情

Rescue of Beta-Adrenergic Cardiomyopathy by Inhibition of Adenylyl Cyclase

Rescue of Beta-Adrenergic Cardiomyopathy by Inhibition of Adenylyl Cyclase
通过抑制腺苷酸环化酶来挽救β-肾上腺素能心肌病
批准号:
8729732
负责人:
Dorothy Eileen Vatner
金额:
$10.48万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-03-16 至 2014-11-30

项目摘要

项目成果

Dorothy Eileen Vatner的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The sympathetic nervous system is critically involved in the pathogenesis of heart failure (HF). It is now currently well recognized from clinical studies that inhibiting sympathetic activity is salutary in HF. Whereas this approach is now routine clinically there are some limitations to the usefulness of this therapeutic approach of inhibiting sympathetic activity at the level of ¿-adrenergic receptors (¿-AR) in some patients with HF. The overall goal of this project is to explore the role of inhibiting ¿-AR at the level of adenylyl cyclase (AC) and to study a potentially new therapeutic approach for HF, i.e., inhibition of type 5 adenylyl cyclase (AC5). Our overall hypothesis is that AC5 is a key enzyme mediating cardiomyopathy in response to cardiac overload and secondarily to increased ¿-AR signaling or to cardiomyopathy induced by chronically enhanced ¿-AR signaling in mice with overexpressed ¿1-AR or ¿2-AR and that inhibition of AC5 rescues the cardiomyopathy in these transgenic (Tg) mice. One might suppose that reducing AC activity will, by itself, be responsible for rescuing ¿-AR cardiomyopathy. However, the main source of AC activity in the heart is AC6, and, since we have demonstrated that AC5 KO only exhibit a 25-30% reduction in AC activity, the rescue of ¿2-AR Tg cardiomyopathy must involve a complex interaction of mechanisms, not simply due to the modest decrease in AC activity. The goal of this project is to determine the mechanisms underlying rescue of cardiomyopathy by inhibition of AC5, which will support the clinical use of this molecule as a novel treatment for HF. There are three major hypotheses: Hypothesis A: Inhibition of AC5 protects against cell death and rescues the cardiomyopathy induced by overexpressed ¿1-AR or ¿2-AR. Hypothesis B: The rescue of the ¿1-AR Tg or ¿2-AR Tg cardiomyopathies by inhibition of AC5 permits enhanced exercise performance which is due to (1) improved cardiac output and stroke volume, (2) improved coronary reserve, and (3) enhanced nitric oxide (NO) signaling. Hypothesis C: Resistance to oxidative stress is an important mechanism in the protection against cell death and rescue of cardiomyopathy in ¿1-AR Tg x AC5 knockout (KO) or ¿2-AR Tg x AC5 KO bigenic mice. The implications for Public Health are self-evident, considering that heart disease and HF are the disease processes which have the greatest impact on Public Health in the US, in terms of finances and task-force, and using similar logic, finding new therapies will be crucial to minimize the impact of these disease states on Public Health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction
  • 批准号:
    9764847
  • 项目类别:
  • 资助金额:
    $67.34万
  • 财政年份:
    2018
  • 负责人:
    Dorothy Eileen Vatner
  • 依托单位:
INHIBITION OF ADENYLYL CYCLASE TYPE 5: HEALTHFUL AGING PROTECTION
  • 批准号:
    9321949
  • 项目类别:
  • 资助金额:
    $19.88万
  • 财政年份:
    2016
  • 负责人:
    Dorothy Eileen Vatner
  • 依托单位:
Mechanisms of myocardial ischemia and reperfusion
  • 批准号:
    8774406
  • 项目类别:
  • 资助金额:
    $7.95万
  • 财政年份:
    2013
  • 负责人:
    Dorothy Eileen Vatner
  • 依托单位:
SFRP2, cell survival, and coronary vascular angiogenesis
  • 批准号:
    8875747
  • 项目类别:
  • 资助金额:
    $45.27万
  • 财政年份:
    2013
  • 负责人:
    Dorothy Eileen Vatner
  • 依托单位:
国内基金
海外基金
人附睾蛋白4靶向调控TGF beta-smad轴加剧克罗恩病相关肠纤维化进程的作用机制研究
AP2B通过WNT/BETA-CATENIN调控颅骨元件成骨活性差异的 分子机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    孙贤杰
  • 依托单位:
TGF-beta通路通过降低自噬-基因组稳定性介导胶质母细胞瘤间质亚型替莫唑胺耐药的机制研究
  • 批准号:
    82303919
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    陈鹭跃
  • 依托单位: